Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02489006 | A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer(NEO) | active not recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 4 | Jun 23, 2026 | clinicaltrials |
| NCT03016338 | Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 51 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 |
| clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT03476681 | Study of NEO-201 in Solid Tumors Expansion Cohorts | active not recruiting | Phase 1 / Phase 2 | 121 | Precision Biologics, IncINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer(EMBER) | active not recruiting | Phase 1 | 379 | Eli Lilly and CompanyINDUSTRY | 8 | Jun 22, 2026 | clinicaltrials |
| NCT04770090 | Research of Circulating Tumor Cells Released During Cervical Cancer Surgery(CTC-COL) | active not recruiting | N/A | 200 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | active not recruiting | Phase 3 | 77 | PfizerINDUSTRY | 19 | Jun 22, 2026 | clinicaltrials |
| NCT05143970 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors(CHANCES) | active not recruiting | Phase 1 | 27 | Institut Paoli-CalmettesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07660718 | The Use of Artificial Intelligence for Ultrasound Screening of Ovarian Cancer in Postmenopausal Women(ASTOM) | active not recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03833479 | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation(ATOMICC) | active not recruiting | Phase 2 | 134 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 28 | TakedaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04452526 | I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination(IVaccinate) | active not recruiting | N/A | 372 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06494150 | Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) | active not recruiting | Phase 2 | 37 | University of OklahomaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02726997 | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | active not recruiting | Phase 1 / Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04251416 | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | active not recruiting | Phase 2 | 50 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04494113 | Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy | active not recruiting | Early Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07642791 | Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy. | active not recruiting | N/A | 300 | University of ZurichOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06107868 | Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer(GyneRep) | active not recruiting | Phase 1 | 6 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03939481 | Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer | active not recruiting | — | 1,336 | SWOG Cancer Research NetworkNETWORK | 4 | Jun 8, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT06511726 | Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer(CATPCC-01) | active not recruiting | Phase 2 | 29 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03671811 | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | active not recruiting | Phase 2 | 44 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04454450 | Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer | active not recruiting | N/A | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer(GLORIOSA) | active not recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 22 | Jun 2, 2026 | clinicaltrials |
| NCT07120945 | Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)(Embrace Gyn) | active not recruiting | N/A | 70 | Medtronic - MITGINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03835819 | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) | active not recruiting | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07341100 | Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC | active not recruiting | Phase 2 | 20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT05200559 | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 25 | Alexander B Olawaiye, MDOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06430320 | Ascertaining Longterm Outcomes of Fibroid Treatments(ALOFT) | active not recruiting | — | 700 | Henry Ford Health SystemOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07605507 | Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical Cancer(HYPOCx-iRex) | active not recruiting | N/A | 40 | Siriraj HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03008408 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05359016 | Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique | active not recruiting | N/A | 9,014 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT04219904 | PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04634617 | Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors | active not recruiting | — | 310 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05761951 | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07205497 | QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer(QNACTH) | active not recruiting | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04009148 | Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome | active not recruiting | — | 118 | NYU Langone HealthOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07581873 | Education and Health in Women With Cervical Cancer | active not recruiting | N/A | 28 | Federal University of MaranhaoOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT05691504 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 23, 2026source: clinicaltrials